region
stringclasses 1
value | symbol
stringlengths 1
5
| exchange
stringclasses 8
values | quote_type
stringclasses 2
values | currency
stringclasses 1
value | name
stringlengths 2
84
⌀ | sector
stringclasses 12
values | industry
stringclasses 148
values | close
float64 0
5.92k
⌀ | volume
float64 0
134M
⌀ | market_cap
float64 22.4k
2,794B
⌀ | updated_at
timestamp[ns] | long_business_summary
stringlengths 50
5.19k
⌀ | status
stringclasses 1
value | __index_level_0__
int64 0
7.31k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
US | ZTEK | NCM | EQUITY | USD | Zentek Ltd. | Healthcare | Medical Instruments & Supplies | 1.15 | 14,198 | 116,137,344 | 2023-10-17T21:24:47.944285 | Zentek Ltd. engages in the research and development of graphene and related nanomaterials in Canada. It owns 100% interest in the Albany Graphite project located in Northern Ontario, Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compound. In addition, it develops graphene oxide synthesis and graphene synthesis. The company was formerly known as ZEN Graphene Solutions Ltd. and changed its name to Zentek Ltd. in October 2021. Zentek Ltd. was incorporated in 2008 and is headquartered in Thunder Bay, Canada. | null | 7,301 |
US | ZTO | NYQ | EQUITY | USD | ZTO Express (Cayman) Inc. | Industrials | Integrated Freight & Logistics | 24.01 | 1,413,808 | 19,570,767,872 | 2023-10-17T21:24:53.606675 | ZTO Express (Cayman) Inc. provides express delivery and other value-added logistics services in the People's Republic of China. It offers freight forwarding services; and delivery services for e-commerce and traditional merchants, and other express service users. The company was founded in 2002 and is headquartered in Shanghai, the People's Republic of China. | null | 7,302 |
US | ZTR | NYQ | EQUITY | USD | Virtus Global Dividend & Income Fund Inc. | Financial | Closed-End Fund - Equity | 4.88 | 294,636 | 229,135,328 | 2023-10-17T21:24:59.866302 | Virtus Global Dividend & Income Fund Inc. is a closed-ended balanced mutual fund launched by Virtus Investment Partners, Inc. The fund is co-managed by Virtus Investment Advisers, Inc., Kayne Anderson Rudnick Investment Management LLC and Newfleet Asset Management, LLC. It invests in the public equity and fixed income markets of the United States. The fund seeks to invest in securities of companies operating across diversified sectors. It primarily invests in reasonably priced growth (GARP) stocks of large cap companies and investment grade bonds issued by companies and governments. The fund is actively managed. It benchmarks the performance of its portfolio against a composite index comprised of 60% Russell Developed Large Cap Index and 40% Bloomberg Barclays U.S. Aggregate Bond Index. The fund was formerly known as The Zweig Total Return Fund, Inc. Virtus Global Dividend & Income Fund Inc. was formed on September 30, 1988 and is domiciled in the United States. | null | 7,303 |
US | ZTS | NYQ | EQUITY | USD | Zoetis Inc. | Healthcare | Drug Manufacturers - Specialty & Generic | 175.18 | 1,716,299 | 80,214,835,200 | 2023-10-17T21:25:05.522080 | Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. The company also offers parasiticides; vaccines; anti-infectives; other pharmaceutical products; dermatology; and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products and laboratory; and other non-pharmaceutical products. It markets its products to veterinarians, livestock producers, and pet owners. The company was founded in 1952 and is headquartered in Parsippany, New Jersey. | null | 7,304 |
US | ZUMZ | NMS | EQUITY | USD | Zumiez Inc. | Consumer Cyclical | Apparel Retail | 16.86 | 288,151 | 350,408,832 | 2023-10-17T21:25:11.656491 | Zumiez Inc., together with its subsidiaries, operates as a specialty retailer of apparel, footwear, accessories, and hardgoods for young men and women. The company also offers hardgoods, including skateboards, snowboards, bindings, components, and other equipment. It operates stores in the United States, Canada, Europe, and Australia under the names of Zumiez, Blue Tomato, and Fast Times. The company also operates zumiez.com, zumiez.ca, blue-tomato.com, and fasttimes.com.au e-commerce websites. Zumiez Inc. was founded in 1978 and is headquartered in Lynnwood, Washington. | null | 7,305 |
US | ZUO | NYQ | EQUITY | USD | Zuora, Inc. | Technology | Software - Infrastructure | 8.09 | 784,908 | 1,159,124,992 | 2023-10-17T21:25:18.471236 | Zuora, Inc., together with its subsidiaries, provides cloud-based subscription management platform that enables companies in various industries to launch, manage, and transform into a subscription business. The company offers Zuora platform that acts as an orchestration engine that allows customers quote-to-cash and revenue operations; and Zuora Billing that helps customers to set payment terms, manage hierarchical billing relationships, consolidate invoicing across multiple subscriptions, and tax transactions. It also provides Zuora Revenue, a revenue recognition automation solution; Zuora CPQ for configure, price, and quote various subscription options; Zuora Collect designed to/ handle the complicated function of payments associated with subscription-based businesses; Zephr, a digital subscriber experience platform for digital publishing and media industry; and Zuora Marketplace. It sells its products through its systems integrators, consultants, and ecosystem partners. Zuora, Inc. was incorporated in 2006 and is headquartered in Redwood City, California. | null | 7,306 |
US | ZURA | NCM | EQUITY | USD | Zura Bio Limited | Healthcare | Biotechnology | 6.01 | 50,190 | 257,202,832 | 2023-10-17T21:25:24.266574 | Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California. | null | 7,307 |
US | ZVIA | NYQ | EQUITY | USD | Zevia PBC | Consumer Defensive | Beverages - Non-Alcoholic | 1.97 | 200,596 | 125,188,200 | 2023-10-17T21:25:30.492487 | Zevia PBC, a beverage company, develops, markets, sells, and distributes various carbonated and non-carbonated soft drinks in the United States and Canada. It offers soda, energy drinks, organic tea, mixers, and kidz drinks. The company offers its products through various retail channels, including grocery distributors, national retailers, warehouse club, and natural products retailers, as well as e-commerce channels. It provides its products under the Zevia brand name. The company was founded in 2007 and is headquartered in Encino, California. | null | 7,308 |
US | ZVRA | NMS | EQUITY | USD | Zevra Therapeutics, Inc. | Healthcare | Biotechnology | 4.46 | 159,931 | 164,039,008 | 2023-10-17T21:25:38.163478 | Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077, which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphenidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase II clinical trial. In addition, the company has received FDA approval for AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. The company's product pipeline include, arimoclomol It has collaboration and license agreement with KVK-Tech, Inc. and Commave Therapeutics SA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida. | null | 7,309 |
US | ZVSA | NGM | EQUITY | USD | ZyVersa Therapeutics, Inc. | Healthcare | Biotechnology | 0.1262 | 1,193,973 | 5,313,230 | 2023-10-17T21:25:45.859034 | ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator, which is in Phase 2a clinical trial to the treatment of multiple renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic nephropathy; and IC 100, a monoclonal antibody inflammasome ASC inhibitor that is in preclinical stage for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida. | null | 7,310 |
US | ZWS | NYQ | EQUITY | USD | Zurn Elkay Water Solutions Corporation | Industrials | Pollution & Treatment Controls | 26.82 | 979,683 | 4,676,514,304 | 2023-10-17T21:25:52.278688 | Zurn Elkay Water Solutions Corporation engages in design, procurement, manufacture, and marketing of water management solutions in the United States, Canada, and internationally. It offers water safety and control products, including interceptors, water control and backflow, fire protection, PEX pipings and tubings, valves, fittings, and installation tools under the Zurn and Wilkis brand names. The company also provides flow systems products, comprising point drains, hydrants, fixture carrier systems, chemical drainage systems; and interceptors and separators, acid neutralization systems, and remote monitoring systems under the Zurn and Green Turtle brands. In addition, it develops, manufactures, and markets remote tank monitoring devices, alarm, software, and services. Further, the company offers sensor-operated flush valves under the Aquaflush, AquaSense, and AquaVantage brands; heavy-duty commercial faucets under the AquaSpec brand; water conserving fixtures under the EcoVantage and Zurn One brands; stainless steel products under the Just Manufacturing brand name, which include stainless steel sinks and plumbing fixtures, and various types of sinks, as well as drinking water products, such as dispensing and filtration products. It serves higher education, healthcare, retail, restaurant, hospitality, education, government, and fire protection markets. The company was formerly known as Zurn Water Solutions Corporation. Zurn Elkay Water Solutions Corporation was incorporated in 2006 and is headquartered in Milwaukee, Wisconsin. | null | 7,311 |
US | ZYME | NMS | EQUITY | USD | Zymeworks Inc. | Healthcare | Biotechnology | 7.05 | 347,394 | 491,743,616 | 2023-10-17T21:25:59.892828 | Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include Zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, colorectal, and endometrial cancers; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. The company has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada. | null | 7,312 |
US | ZYNE | NCM | EQUITY | USD | Zynerba Pharmaceuticals, Inc. | Healthcare | Drug Manufacturers - Specialty & Generic | 1.3 | 861,742 | 70,121,216 | 2023-10-17T21:26:07.155471 | Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania. As of October 10, 2023, Zynerba Pharmaceuticals, Inc. operates as a subsidiary of Harmony Biosciences Holdings, Inc. | null | 7,313 |
US | ZYXI | NMS | EQUITY | USD | Zynex, Inc. | Healthcare | Medical Distribution | 8.12 | 226,761 | 293,787,008 | 2023-10-17T21:26:14.863280 | Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and knee braces for knee support. Further, it offers Zynex Fluid Monitoring System (CM-1500), a fluid volume monitor, which is a non-invasive medical device for monitoring relative fluid volume changes used in operating and recovery rooms to detect fluid loss during surgery and internal bleeding during recovery; Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado. | null | 7,314 |